iTeos joins Roche in delaying a TIGIT readout

After Roche's recent delay to the expected final overall survival readout from the phase 3 Skyscraper-01 trial Iteos yesterday said phase 2 data for its GSK-partnered anti-TIGIT MAb belrestotug would slip into 2024. The phase 2 trial in question, in first-line NSCLC patients with ≥50% PD-L1 expression where belrestotug plus Jemperli is being pitted versus Merck & Co's Keytruda, had earlier been expected to yield data in the third quarter of 2023. A phase 3 trial is still planned by Iteos/GSK in this setting, although Iteos's second-quarter financials release provided no specific timeline. Earlier, at Roche's second-quarter earnings call, the Swiss group said final OS data from Skyscraper-01 would come in the fourth quarter of 2023 or first quarter of 2024, having earlier guided to a second-half readout. At first analysis in May 2022 Skyscraper-01 failed to meet the co-primary endpoint of PFS, and first OS analysis this year failed to trigger stopping criteria.